<p>The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.</p>
申请公布号
WO2007146730(A3)
申请公布日期
2008.02.14
申请号
WO2007US70582
申请日期
2007.06.07
申请人
GLOUCESTER PHARMACEUTICALS;THE GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES;MCCULLOCH, WILLIAM;PIEKARZ, RICHARD, L.;BATES, SUSAN, E.
发明人
MCCULLOCH, WILLIAM;PIEKARZ, RICHARD, L.;BATES, SUSAN, E.
